Jazz Pharmaceuticals JAZZ Deferred Other Tax Expense Benefit
Deferred Other Tax Expense Benefit at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredOtherTaxExpenseBenefit.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's deferred other tax expense benefit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's deferred other tax expense benefit?
- Jazz Pharmaceuticals (JAZZ) reported deferred other tax expense benefit of -$3.4M in Q4 2025.
- How has Jazz Pharmaceuticals's deferred other tax expense benefit changed year-over-year?
- Jazz Pharmaceuticals's deferred other tax expense benefit decreased by 18.3% year-over-year, from -$2.87M to -$3.4M.
- What is the long-term trend for Jazz Pharmaceuticals's deferred other tax expense benefit?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's deferred other tax expense benefit has grown at a -17.0% compound annual growth rate (CAGR), from -$28.6M to -$13.58M.
- What does deferred other tax expense benefit mean?
- The net impact of miscellaneous temporary tax differences on future tax liabilities.
- How do you interpret deferred other tax expense benefit?
- An increase indicates a rise in deferred tax assets or a reduction in deferred tax liabilities, while a decrease suggests the opposite.
- How does deferred other tax expense benefit compare across companies?
- Common in companies with complex tax structures and significant temporary book-tax differences.